ABIVAX Société Anonyme (BATS-CHIXE:ABVXp) - Stock Price, News & Analysis

ABVXp Stock Overview

A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.

About the company

ABVXp fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 54.33% per year

Risk Analysis

Earnings are forecast to decline by an average of 19.1% per year for the next 3 years

Makes less than USD$1m in revenue (€20K)

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

+ 1 more risk

ABIVAX Société Anonyme Competitors

Avacta Group

AIM:AVCT

UK£153.5m

PureTech Health

LSE:PRTC

UK£618.7m

Oxford Biomedica

LSE:OXB

UK£326.0m

Bioventix

AIM:BVXP

UK£227.1m

Price History & Performance

Summary of all time highs, changes and price drops for ABIVAX Société Anonyme
Historical stock prices
Current Share Price	€16.22
52 Week High	€16.50
52 Week Low	€6.01
Beta	1.32
1 Month Change	0%
3 Month Change	n/a
1 Year Change	110.10%
3 Year Change	-26.10%
5 Year Change	46.65%
Change since IPO	-21.57%

Recent updates

Shareholder Returns

	ABVXp	GB Biotechs	GB Market
7D	0%	1.9%	0.5%
1Y	110.1%	-20.4%	6.3%

Return vs Industry: ABVXp exceeded the UK Biotechs industry which returned -28.7% over the past year.

Return vs Market: ABVXp exceeded the UK Market which returned -2.4% over the past year.

Price Volatility

Is ABVXp's price volatile compared to industry and market?
ABVXp volatility
ABVXp Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: ABVXp has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ABVXp's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	26	Marc M. de Garidel	www.abivax.com

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
ABVXp fundamental statistics
Market cap	€602.03m
Earnings (TTM)	-€91.51m
Revenue (TTM)	€20.00k

Over9,999x

P/S Ratio

-6.6x

P/E Ratio

Is ABVXp overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABVXp income statement (TTM)
Revenue	€20.00k
Cost of Revenue	€0
Gross Profit	€20.00k
Other Expenses	€91.53m
Earnings	-€91.51m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.46
Gross Margin	100.00%
Net Profit Margin	-457,550.00%
Debt/Equity Ratio	50.1%

How did ABVXp perform over the long term?

See historical performance and comparison

ABVXp Stock Overview

Rewards

Risk Analysis

ABIVAX Société Anonyme Competitors

AIM:AVCT

UK£153.5m

LSE:PRTC

UK£618.7m

LSE:OXB

UK£326.0m

AIM:BVXP

UK£227.1m

Price History & Performance

Recent News & Updates

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

Recent updates

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Shareholder Returns

Price Volatility

About the Company

ABIVAX Société Anonyme Fundamentals Summary

Over9,999x

-6.6x

Earnings & Revenue